2017

1. Efficacy and safety of the biosimilar ABP 501 compared with adalimumab in patients with moderate to severe rheumatoid arthritis: A randomised, double-blind, phase III equivalence study

   Annals of the Rheumatic Diseases, Vol. 76, Núm. 10, pp. 1679-1687